# US 2025/0375315 A1 · Method and device for treating and managing diseased ocular tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375315 A1
- Document ID: US20250375315A1
- Status: Published application
- Kind: A1
- Application number: 19/301,463
- Filed: 2025-08-15
- Published: 2025-12-11
- Earliest claimed: 2020-12-07
- Inventors: Sara Heikali; Moossa Heikali
- Web page: https://patentgrep.com/patent/US20250375315A1

## CPC

- A61F 9/007: Methods or devices for eye surgery
- A61F 9/00736: {Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments (A61F9/008 takes precedence)}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 9/0051: {Ocular inserts or implants}
- A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts}
- A61F 9/00781: {Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment (drainage implants in general A61M27/002)}
- A61F 2210/0004: bioabsorbable
- A61F 2220/0016: with sharp anchoring protrusions, e.g. barbs, pins, spikes
- A61F 2250/0031: made from both resorbable and non-resorbable prosthetic parts, e.g. adjacent parts
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61L 2430/16: for reconstruction of eye parts, e.g. intraocular lens, cornea
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

A method comprises treating an ocular condition resulting from an MMP imbalance comprising: applying to the ocular tissue an effective amount of a therapeutic composition, wherein said therapeutic composition comprises a first MMP inhibitor comprising EDTA.

## Claims

### Claim 1

A method of treating an ocular condition resulting from an MMP imbalance comprising:
applying to the ocular tissue an effective amount of a therapeutic composition,
wherein said therapeutic composition comprises a first MMP inhibitor comprising EDTA.

### Claim 2 (depends on 1)

The method of claim 1, further comprising a second MMP inhibitor, wherein the first MMP inhibitor and second MMP inhibitors are different.

### Claim 3 (depends on 2)

The method of claim 2, wherein the effective amount of the therapeutic composition comprises greater than 0.2% EDTA by weight of the composition.

### Claim 4 (depends on 3)

The method of claim 3, wherein the first MMP inhibitor is not used a preservative.

### Claim 5 (depends on 4)

The method of claim 4, wherein the first MMP inhibitor inhibits the activity of MMP 1, 2, 3 or 9 in the ocular tissue.

### Claim 6 (depends on 5)

The method of claim 5, wherein the second MMP inhibitor inhibits the activity of MMP 2 and MMP 9 in the ocular tissue.

### Claim 7 (depends on 6)

The method of claim 6, wherein application of the therapeutic composition comprises administering an eye drop to the ocular tissue at least once a day for at least fourteen days.

### Claim 8 (depends on 1)

The method of claim 1, wherein the therapeutic composition comprises an aqueous solvent.

### Claim 9 (depends on 1)

The method of claim 1, wherein the ocular condition is a disease, disorder, degenerative condition, or any other abnormal ocular conditions.

### Claim 10 (depends on 9)

The method of claim 9, wherein the ocular condition comprises pinguecula, pterygium or dry eyes or any other condition resulting from an imbalance of MMP and TIMP.

### Claim 11

A method of treating an ocular condition comprising,
i) creating a plurality of micro-injury sites in the ocular tissue; and
ii) applying an effective amount of a therapeutic composition to the micro-injury sites,
wherein said therapeutic composition comprises a first MMP inhibitor comprising EDTA.

### Claim 12 (depends on 11)

The method of claim 11, wherein the therapeutic composition further comprises a second MMP inhibitor, wherein the first MMP inhibitor and second MMP inhibitors are different.

### Claim 13 (depends on 12)

The method of claim 12, comprising creating a plurality of micro-injury sites using microneedles coated or impregnated with the therapeutic composition.

### Claim 14

A contact lens comprising a therapeutic composition comprising a first MMP inhibitor comprising EDTA.

### Claim 15 (depends on 14)

The contact lens of claim 14, further comprising a second MMP inhibitor, wherein the first MMP inhibitor and second MMP inhibitors are different.

### Claim 16

A method of treating an ocular condition comprising the steps of:
administering to the eye of a subject in need thereof a therapeutic composition comprising
(a) a first MMP inhibitor comprising 0.1%-10.0% (wt.) EDTA or a derivative, analog, or pharmaceutically acceptable salt thereof;
(b) a second MMP inhibitor comprising 0.1%-10% (wt.) of an MMP9 inhibitor, wherein the first MMP inhibitor and second MMP inhibitor are different; and
wherein the administration of a unit dose of the therapeutic composition comprises a single eye drop providing sustained release of the first MMP inhibitor or derivative, analog, or pharmaceutically acceptable salt thereof and the second MMP inhibitor, in the eye for at least two days and administration is repeated at least once every day.

### Claim 17 (depends on 16)

The method of claim 16, wherein the therapeutic compositions comprises at least twice the amount of the second MMP inhibitor than the first MMP inhibitor.

### Claim 18 (depends on 16)

The method of claim 16, wherein the therapeutic composition comprises 0.2%-3.0% of the first MMP inhibitor.

### Claim 19 (depends on 18)

The method of claim 18, wherein the therapeutic composition comprises 0.2%-10% (wt.) of the second MMP inhibitor.

### Claim 20 (depends on 18)

The method of claim 18, wherein ocular condition comprises pinguecula, pterygium or dry eyes or any other condition resulting from an imbalance of MMP and TIMP.
